Hepatocellular carcinoma: From diagnosis to treatment. (June 2016)

• Record Type: Journal Article
• Authors: Grandhi, Miral Sadaria; Kim, Amy K.; Ronnekleiv-Kelly, Sean M.; Kamel, Ihab R.; Ghasebeh, Mounes A.; Pawlik, Timothy M.
• Is Part Of: Surgical oncology. Volume 25:Number 2(2016)
• Page Start: 74
• Page End: 85
• Publication Date: 2016-06
• Subjects: Hepatocellular carcinoma -- Liver transplantation -- Ablation -- Transarterial chemoembolization (TACE) -- Functional MRI -- Sorafenib; Cancer -- Surgery -- Periodicals; Neoplasms -- surgery -- Periodicals; Cancer -- Chirurgie -- Périodiques; Electronic journals; 616.994059
• DOI: 10.1016/j.suronc.2016.03.002
• Languages: English
• ISSNs: 0960-7404

Abstract

Abstract: Primary liver cancer is the sixth most common cancer overall and the second most common cause of cancer mortality worldwide. Hepatocellular carcinoma accounts for up to 90% of all primary hepatic malignancies and represents a major international health problem. While surgical resection and transplantation are the cornerstone of therapy in early-stage hepatocellular carcinoma, locoregional therapy and sorafenib are beneficial in those with more advanced disease or those who are not surgical candidates. At times, the integration of both surgical and locoregional therapy may be necessary. Hence, hepatocellular carcinoma requires a multidisciplinary approach to determine the most appropriate treatment as well as the timing of various treatments for optimal outcomes.